FDA approves low dose Bijuva for treatment of moderate to severe vasomotor symptoms
Posted on April 26, 2022
Source: Pharmacy Times
The U.S. Food and Drug Administration approved a 0.5 mg/100 mg dose of TherapeuticsMD Inc.'s Bijuva hormone therapy. This low-dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to menopause, is 0.5 milligrams (mg) of estradiol and 100 mg of progesterone (0.5/100mg).
In 2018, the FDA approved Bijuva for the treatment of moderate to severe vasomotor symptoms of menopause at the 1mg of estradiol and 100 mg of progesterone (1/100 mg) dose.
To learn more about which dose would work for you, talk with your doctor.